What is the New Injectable Drug for Schizophrenia? Examining Latest Approvals
•
2 min read
In September 2025, Amneal Pharmaceuticals received U.S. FDA approval for its Risperidone Extended-Release Injectable Suspension, marking the most recent addition to the long-acting injectable options for schizophrenia. This provides another valuable tool for clinicians and patients in managing this chronic condition, addressing the critical issue of treatment adherence.
